{"schema_version":"secwatch.filing_event.v1","accession":"0001439222-23-000117","form_type":"8-K","ticker":"AGIO","cik":"0001439222","company_name":"AGIOS PHARMACEUTICALS, INC.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.930857+00:00","generated_at":"2026-06-12T07:47:33.203851+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Agios Q2 2023: PYRUKYND revenue $6.7M; net loss $83.8M; pipeline advances","bullets":["PYRUKYND net revenue $6.7M in Q2, up 20% QoQ; 147 patients completed enrollment forms, 99 on therapy.","Net loss $83.8M vs $91.8M a year ago; cash $946.9M, expected runway into 2026.","Phase 2 mitapivat in sickle cell positive; Phase 3 enrollment to begin Q4 2023.","Completed enrollment in Phase 3 thalassemia studies (ENERGIZE/ENERGIZE-T) and Phase 2a AG-946 in LR-MDS.","Licensed Alnylam siRNA for polycythemia vera; appointed Catherine Owens to board."],"urls":{"canonical":"https://secwatch.observer/filing/0001439222-23-000117","json":"https://secwatch.observer/filing/0001439222-23-000117.json","markdown":"https://secwatch.observer/filing/0001439222-23-000117.md","text":"https://secwatch.observer/filing/0001439222-23-000117.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000117/0001439222-23-000117-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000117/agio-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T07:47:33.203851+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4f2cc4d72ab9f966ce5e999d8a76e07e41f8a761","claim":"AGIOS PHARMACEUTICALS, INC. reported the second quarter ended June 30, 2023 results: revenue $6.7 million, net income $83.8 million.","evidence_excerpt":"License Agreement with Alnylam Pharmaceuticals to License Alnylam’s Novel siRNA for the Potential Treatment of Polycythemia Vera – U.S. PYRUKYND ® (mitapivat) Net Revenue of $6.7 Million in Q2; $947 Million of Cash, Cash Equivalents and Marketable Securities as of June 30, 2023 CAMBRIDGE, Mass., August 3, 2023 -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000117/0001439222-23-000117-index.htm","confidence":0.65,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$6.7 million"},{"label":"Net income","value":"$83.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}